Report Highlights

Antihelminthics in the U.S.: Market Overview

The U.S. antihelminthics market generated USD 1.45 billion in 2024, with animal health accounting for roughly three-quarters of revenue and human-use products making up the remainder. Its structure is shaped by the Federal Food, Drug, and Cosmetic Act, which requires FDA approval before any anthelmintic can be marketed, and by the Animal Drug User Fee Act, which funds faster review cycles. Government has been the dominant force in human-use demand through CDC treatment guidance and Medicaid reimbursement, while private firms lead companion and livestock segments through product launches.

Policy has shaped the current form of the market through the Minor Use and Minor Species Animal Health Act of 2004 (MUMS), which granted extended exclusivity incentives for drugs used in goats, sheep, and horses. Zoetis, Boehringer Ingelheim Animal Health, and Elanco Animal Health hold most branded livestock and companion-animal franchises, while low-cost generic ivermectin and albendazole supply is concentrated among Norbrook Laboratories and Bimeda. The result is a two-tier structure: patent-protected combination products in companion animals and price-competitive generics in livestock.

Policy-Driven Growth in U.S. Antihelminthics

The MUMS Act amended the Federal Food, Drug, and Cosmetic Act to create incentives for approvals in minor species, which previously lacked labelled antiparasitic products. This mechanism drives growth because sponsors now invest in small-ruminant and equine label expansions, particularly for moxidectin and fenbendazole formulations. The Animal Drug User Fee Act, reauthorized for fiscal years 2024 through 2028, funds FDA Center for Veterinary Medicine review staff, shortening review cycles for generic ANADA filings for ivermectin and albendazole and expanding low-cost supply.

Human-use demand is supported by the Tropical Disease Priority Review Voucher programme under Section 524 of the Federal Food, Drug, and Cosmetic Act, which awards vouchers to sponsors of approved neglected tropical disease therapies. Vouchers have traded at roughly USD 100 million on secondary markets, which recovers development costs and encourages pipeline investment in helminth treatments such as triclabendazole. Medicaid reimbursement and CDC treatment guidance for strongyloidiasis and neurocysticercosis keep albendazole and ivermectin volumes stable among uninsured and immigrant patient populations.

Regulatory Barriers and Compliance Costs

Every new anthelmintic must clear FDA Center for Veterinary Medicine review under Section 512 of the Federal Food, Drug, and Cosmetic Act before marketing, and a full new animal drug application typically takes 12 to 24 months. Efficacy and residue studies often push development costs above USD 20 million per product. Residue tolerances under 21 CFR Part 556 also set slaughter withdrawal periods, which add delay and lost sales to every cattle and sheep product brought to market.

Human-use products fall under the Drug Supply Chain Security Act, enforced by FDA, which requires product serialization and electronic transaction information at each distribution step. Small repackagers and independent pharmacies bear a disproportionate share of these costs, often requiring dedicated software and staff for each site. Medicaid Average Manufacturer Price calculations further constrain pricing, so manufacturers of generic albendazole face narrow margins despite steady demand.

Policy-Created Opportunities in U.S. Antihelminthics

MUMS-driven exclusivity creates an opening for generic and mid-size manufacturers to file for small-ruminant labels that large sponsors have not prioritised. Norbrook Laboratories and Bimeda are positioned to capture goat and sheep antiparasitic volumes, since minor-species approvals reward first filers with protected market windows. Equine producers present a similar opportunity, where moxidectin-based products face limited branded competition in specific dosing forms.

Tariff measures and the August 2025 executive order establishing a Strategic Active Pharmaceutical Ingredients Reserve have increased scrutiny of ivermectin and albendazole active ingredients sourced largely from India and China. This creates an opportunity for domestic or allied API producers to secure federal procurement contracts and private supply agreements. Manufacturers that qualify U.S.-based API sources ahead of rival tariff exposure will gain pricing leverage with distributors and government buyers.

Market at a Glance

Leading Market Participants

• Zoetis
• Boehringer Ingelheim Animal Health
• Elanco Animal Health
• Merck Animal Health
• Merck & Co.
• Virbac
• Norbrook Laboratories
• Bimeda
• Amneal Pharmaceuticals
• Bayer HealthCare

Regulatory and Policy Environment

The primary legislation governing this market is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), administered by the FDA Center for Veterinary Medicine for animal products and the Center for Drug Evaluation and Research for human products. Compliance requires New Animal Drug Applications or ANADA filings, residue tolerance data under 21 CFR Part 556, and labelling aligned with Animal Drug User Fee Act performance commitments. ADUFA commitments run through September 30, 2028, and the Tropical Disease Priority Review Voucher programme is scheduled to sunset on September 30, 2026 unless Congress extends it.

Compared with regional peers, the U.S. framework offers faster generic entry than the European Union, where Regulation (EU) 2019/6 on veterinary medicinal products, applying from 28 January 2022, adds centralised EMA review layers and stricter antimicrobial stewardship requirements. Health Canada's Veterinary Drugs Directorate operates a similar pathway, but U.S. generic approvals through ANADA remain faster for established ivermectin and albendazole molecules. Mexico's COFEPRIS framework relies heavily on reference approvals from U.S. and European regulators.

Long-Term Policy Outlook for U.S. Antihelminthics

By 2032, the ADUFA reauthorization cycle beginning in 2028 is expected to tighten performance goals for generic review and expand data requirements for anthelmintic resistance monitoring. Congress will decide whether the Tropical Disease Priority Review Voucher programme is extended beyond its 2026 sunset, which directly determines whether helminth therapy investment continues at current levels. Both decisions will shape which products reach market and how quickly.

Tariffs and strategic API reserve policy are likely to reshape supply chains by 2032, shifting ivermectin and albendazole production toward domestic and allied manufacturers. Producers that secure U.S.-sourced intermediates will hold pricing power as federal and private buyers prioritise supply security. Resistance-driven product substitution will also accelerate, concentrating livestock volume among moxidectin and newer macrocyclic lactone formulations.